Most Read Articles
Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 3 days ago

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Dr. Jason Butler, 01 Apr 2020
Proteasome inhibitors have become a cornerstone of therapy for multiple myeloma (MM). At the Hong Kong Society of Myeloma Annual Scientific Meeting 2019, Dr Jason Butler of the Icon Cancer Care & Royal Brisbane and Women’s Hospital, Brisbane, Australia, reviewed current evidence for the use of proteasome inhibitors in the management of relapsed/refractory MM (R/R MM), with a focus on the efficacy and safety profile of carfilzomib.
Natalia Reoutova, 2 days ago

Results of the world’s first-in-human phase I clinical trial of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 PD-1–edited T cells, recently published in Nature Medicine, suggest therapy’s feasibility in refractory non-small-cell lung cancer (NSCLC), with no severe treatment-related adverse events (TRAEs).

Rationale and clinical evidence for the use of tumour-treating fields in the treatment of glioblastoma and other cancers

24 Apr 2020
Tumour-treating fields (TTFields) are a non-invasive anticancer treatment modality that utilizes low-intensity, intermediate-frequency (100–300 kHz), alternating electric fields delivered through transducer arrays placed around the tumour region to inhibit tumour cell division.  

These TTFields affect various charged and polar molecules within rapidly dividing cancer cells. Through interfering with the structure of microtubules and the movement of organelles during cell division, TTFields cause abnormal mitosis, leading to cell death, blocking of cell division or the formation of lethal chromosomal aberrations. 

Sponsored as a service to the medical profession by Zailab Optune.Editorial development by MIMS MedComms.The opinions expressed in this publication are not necessarily those of the editor, publisher or sponsor.Any liability or obligation for loss or damage howsoever arising is hereby disclaimed.© 2020 MIMS (Hong Kong) Limited. All rights reserved.No part of this publication may be reproduced by any process in any language without the written permission of the publisher
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 3 days ago

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Dr. Jason Butler, 01 Apr 2020
Proteasome inhibitors have become a cornerstone of therapy for multiple myeloma (MM). At the Hong Kong Society of Myeloma Annual Scientific Meeting 2019, Dr Jason Butler of the Icon Cancer Care & Royal Brisbane and Women’s Hospital, Brisbane, Australia, reviewed current evidence for the use of proteasome inhibitors in the management of relapsed/refractory MM (R/R MM), with a focus on the efficacy and safety profile of carfilzomib.
Natalia Reoutova, 2 days ago

Results of the world’s first-in-human phase I clinical trial of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 PD-1–edited T cells, recently published in Nature Medicine, suggest therapy’s feasibility in refractory non-small-cell lung cancer (NSCLC), with no severe treatment-related adverse events (TRAEs).